Core Insights - Allarity Therapeutics is focused on advancing stenoparib, a dual PARP and WNT pathway inhibitor, for the treatment of advanced ovarian cancer and other difficult-to-treat cancers [1][2][10] Group 1: Strategic Developments - In 2024, Allarity underwent a strategic reset, focusing exclusively on stenoparib and shedding legacy programs to enhance its therapeutic potential [2][3] - The company achieved FDA Fast Track Designation for stenoparib, indicating a significant step towards clinical and regulatory success [2] - Allarity simplified its capital structure and resolved legacy SEC matters, improving its corporate and financial foundations [3][4] Group 2: Clinical Progress - In 2025, Allarity accelerated stenoparib's path to FDA approval while expanding its clinical potential to recurrent Small Cell Lung Cancer [5][6] - Updated clinical data showed that median Overall Survival for patients on stenoparib had not been reached, with some patients remaining on therapy for over 30 months [6][10] - A new Phase 2 trial protocol was initiated to confirm and extend the clinical benefits of stenoparib [6][10] Group 3: Financial Health - The company maintained a disciplined operating model, aligning its cash runway with development objectives and managing expenses rigorously [9] - Selective share repurchases were made to enhance shareholder value while preserving financial stability [9] Group 4: Future Outlook - Looking ahead to 2026, Allarity aims to deepen and accelerate the advancement of stenoparib towards approval and explore additional cancer indications [11][12] - The foundation laid over the past two years is expected to support meaningful progress across clinical, regulatory, and strategic dimensions [12]

As filed with the Securities and Exchange Commission on March 14, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Allarity Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 87-2147982 (Primary Standard Industrial Classification Code Number) 24 School Street, 2nd Floor Boston, MA 02108 Telephon ...